Research Analysts’ Recent Ratings Changes for Glaukos (GKOS)

Glaukos (NYSE: GKOS) recently received a number of ratings updates from brokerages and research firms:

• 2/7/2026 – Glaukos was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/30/2026 – Glaukos was upgraded by analysts at William Blair to a “strong-buy” rating.
• 1/28/2026 – Glaukos had its price target raised by analysts at BTIG Research from $123.00 to $131.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Glaukos had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/22/2026 – Glaukos had its price target raised by analysts at Stifel Nicolaus from $115.00 to $160.00. They now have a “buy” rating on the stock.
• 1/14/2026 – Glaukos had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $165.00 price target on the stock.
• 1/14/2026 – Glaukos had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $125.00 price target on the stock.
• 1/9/2026 – Glaukos had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $138.00 price target on the stock.
• 1/2/2026 – Glaukos had its price target raised by analysts at Stephens from $115.00 to $145.00. They now have an “overweight” rating on the stock.
• 1/2/2026 – Glaukos had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $116.00 price target on the stock.
• 12/23/2025 – Glaukos had its price target raised by analysts at UBS Group AG from $140.00 to $145.00. They now have a “buy” rating on the stock.
• 12/18/2025 – Glaukos had its price target raised by analysts at Truist Financial Corporation from $120.00 to $145.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Glaukos was given a new $165.00 price target on by analysts at UBS Group AG.
• 12/17/2025 – Glaukos had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $61.00 price target on the stock.
• 12/11/2025 – Glaukos had its price target raised by analysts at Citigroup Inc. from $113.00 to $125.00. They now have a “buy” rating on the stock.

Insider Activity

In other Glaukos news, CFO Alex R. Thurman sold 315 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total transaction of $33,075.00. Following the sale, the chief financial officer owned 50,488 shares in the company, valued at $5,301,240. This trade represents a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Thomas William Burns sold 186,945 shares of the company’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $115.00, for a total value of $21,498,675.00. Following the completion of the transaction, the chief executive officer owned 153,775 shares of the company’s stock, valued at $17,684,125. The trade was a 54.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 329,655 shares of company stock worth $37,752,234. Corporate insiders own 6.40% of the company’s stock.

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.